Human stresscopin is a corticotropin-releasing factor (CRF) type 2 receptor (CRFR2) selective agonist and a member of the CRF peptide family. Stimulation of CRFR2 improves cardiac output and left ventricular ejection fraction (LVEF) in patients with stable heart failure (HF) with reduced LVEF. We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF with LVEF ≤ 35% and cardiac index (CI) ≤ 2.5 L/min/m(2).
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction / Gheorghiade, Mihai; Greene, Stephen J; Ponikowski, Piotr; Maggioni, Aldo P; Korewicki, Jerzy; Macarie, Cezar; Metra, Marco; Grzybowski, Jacek; Bubenek Turconi, Serban Ion; Radziszewski, Waldemar; Olson, Allan; Bueno, Orlando F; Ghosh, Atalanta; Deckelbaum, Lawrence I; Li, Lilian Y; Patel, Ayan R; Koester, Andreas; Konstam, Marvin A.. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 15:6(2013), pp. 679-689. [10.1093/eurjhf/hft023]
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
METRA, Marco;
2013-01-01
Abstract
Human stresscopin is a corticotropin-releasing factor (CRF) type 2 receptor (CRFR2) selective agonist and a member of the CRF peptide family. Stimulation of CRFR2 improves cardiac output and left ventricular ejection fraction (LVEF) in patients with stable heart failure (HF) with reduced LVEF. We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF with LVEF ≤ 35% and cardiac index (CI) ≤ 2.5 L/min/m(2).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
